Phase-2-Daten für Prüfpräparat Acasunlimab (DuoBody® -PD-L1x4-1BB) in Kombination mit Pembrolizumab: Signifikante klinische Aktivität bei vorbehandeltem, metastasiertem nicht-kleinzelligem Lungenkarzinom
June 01, 2024 10:00 ET
|
BioNTech SE
Erste Daten aus einer laufenden Phase-2-Studie zeigten eine 12-Monats-Gesamtüberlebensrate von 69 % und ein medianes Gesamtüberleben von 17,5 Monaten bei Patientinnen und Patienten mit vorbehandeltem,...
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
June 01, 2024 10:00 ET
|
BioNTech SE
Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with previously treated PD-L1-positive metastatic...
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer
June 01, 2024 08:00 ET
|
Purple Biotech Ltd.
26% reduction in risk of death (HR=0.74) and 28% risk reduction in progression or death (HR=0.72) in previously-treated patients administered with CM24+nivolumab+Nal/IRI/5FU/LV vs....
Subsea7 awarded four PLSV contracts in Brazil
June 01, 2024 03:23 ET
|
Subsea 7 (Uk Service Co) Ltd
Luxembourg – 1 June 2024 - Subsea 7 S.A. (Oslo Børs: SUBC, ADR: SUBCY) today announced, after a competitive tender process, the award by Petrobras of four long-term day-rate contracts for pipelay...
The Boston Beer Company Statement on Company Sale Speculation
May 31, 2024 18:07 ET
|
Boston Beer Company
Boston, May 31, 2024 (GLOBE NEWSWIRE) -- The Boston Beer Company, Inc. (NYSE: SAM) is aware of today’s Wall Street Journal article on company sale speculation. We do not comment on rumors. We are...
Johnson & Johnson submits application to the European Medicines Agency seeking approval of subcutaneous formulation of RYBREVANT®▼ (amivantamab) for the treatment of patients with EGFR-mutated non-small cell lung cancer
May 31, 2024 17:50 ET
|
Janssen Cilag International NV
Submission is supported by data from the Phase 3 PALOMA-3 study featured at the American Society of Clinical Oncology (ASCO) Annual Meeting1New formulation showed non-inferiority to intravenous...
Nokia Oyj: Omien osakkeiden takaisinosto 31.05.2024
May 31, 2024 15:30 ET
|
Nokia Oyj
Nokia OyjPörssitiedote31.05.2024 klo 22.30 Nokia Oyj: Omien osakkeiden takaisinosto 31.05.2024 Espoo – Nokia Oyj (LEI: 549300A0JPRWG1KI7U06) on 31.05.2024 hankkinut omia osakkeitaan (ISIN...
Nokia Corporation: Repurchase of own shares on 31.05.2024
May 31, 2024 15:30 ET
|
Nokia Oyj
Nokia CorporationStock Exchange Release31 May 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 31.05.2024 Espoo, Finland – On 31 May 2024 Nokia Corporation (LEI:...
Gluten-free Certification Organization Withdraws Certification from Best Express Foods
May 31, 2024 13:52 ET
|
Gluten Intolerance Group of N.A.
Auburn, WA, May 31, 2024 (GLOBE NEWSWIRE) -- 05/31/2024 (Auburn, WA) – The Gluten Intolerance Group’s Gluten-free Certification Organization (GFCO) has made the decision to withdraw certification...
The Importance of Reintegrating Displaced People into Communities: ICAAPS’ Commitment to 2nd Chances
May 31, 2024 13:50 ET
|
Illinois Community Action Agency: Programs & Services
Chicago, Illinois, May 31, 2024 (GLOBE NEWSWIRE) -- In a world where people’s judgment is clouded so easily, organizations devoted to helping individuals going through disastrous times are crucial...